|
EMA Updates Biosimilars Guidance, Seeks Broad Quality Comparison
Biosimilars’ molecular characteristics should mirror those of the reference biologic as closely as possible, while the performance and consistency of the biosimilars’ manufacturing process should stand on its own, the European Medicines Agency (EMA) says in updated guidelines.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives